Publication at First Faculty of Medicine |
2011
Abstract
More than five years pass after infliximab therapy starts in UC patients. Currently, infliximab is indicated for chronic active course of UC and in cortico-dependent or cortico-resistant patients, especially.
In the extraordinary situations, infliximab might be used as a rescue therapy in fulminant UC course or in patients with severe extraintestinal complications. Despite the high infliximab efficacy in the short-term, a sustained response or remission is achieved in a half of them in the long-term.
It is necessary to select those UC patients with high probability to obtain a positive results in long-term.